image description

Tag: lupus therapeutics

Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials

NEW YORK, NY. February 1, 2019. Lupus Research Alliance clinical affiliate Lupus Therapeutics launched the Patient Advocates for Lupus Studies (PALS) program with a pilot study to determine its effectiveness in increasing awareness of and participation in lupus clinical trials, particularly among diverse populations.  PALS was formed to address the pressing issue of underrepresentation in clinical studies […] Read More

Overcoming Challenges to Lupus Management

January 24, 2019 A recent review article in Lupus Science & Medicine provides a valuable overview of the “10 most important contemporary challenges in the management of SLE” according to a multidisciplinary team of clinicians, pharmacists and researchers from several clinics and patient organizations in France.  Their top 10 challenges include several critical factors that the […] Read More

Lupus Research Alliance and Lupus Therapeutics Partner on New Phase 3 Trial Testing Potential Benefit of Ustekinumab (Stelara®) in Lupus

The Lupus Research Alliance announced that clinical research affiliate Lupus Therapeutics is partnering with the pharmaceutical company, Janssen, to help conduct a Phase 3 trial to test existing drug ustekinumab (Stelara®) as a potential treatment for people with lupus. Stelara® is not approved by the FDA as a treatment of lupus but is indicated for […] Read More

Bold Initiatives … Tremendous Strides Breaking Through on Lupus Research

In 2018 the Lupus Research Alliance has taken daring chances, pursued bold initiatives, and made tremendous strides! We truly are breaking through on many pioneering fronts of lupus research — thanks to the unwavering generosity of donors at all levels of support. Throughout the year, the brilliant scientists we brought to the table ushered in […] Read More

Albert T. Roy, Executive Director Lupus Therapeutics, LLC

I’m writing this blog because the Lupus Research Alliance, and its affiliate, Lupus Therapeutics is determined to drive discovery and development of new treatments for lupus! I am proud to serve as Executive Director of Lupus Therapeutics, which serves as fiscal and administrative agent of the Lupus Clinical Investigators Network (LuCIN), a network of 57 […] Read More

Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial

New York, NY. April 26, 2018. The Lupus Research Alliance today announced that the newly formed clinical affiliate Lupus Therapeutics will collaborate with the pharmaceutical company, Bristol-Myers Squibb (BMS), to conduct a global trial evaluating the novel investigational drug, BMS-986165, as a potential treatment for people with lupus. BMS-986165 is a highly selective inhibitor of Tyrosine kinase […] Read More